Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

December 6, 2022

https://www.globenewswire.com/news-release/2022/12/06/2568809/0/en/Candel-Therapeutics-R-D-Day-Presentations-Spotlight-its-Advanced-Pipeline-and-Capabilities-to-Develop-Novel-Viral-Immunotherapies-for-Patients-with-Cancer.html

NEEDHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq:CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today held its Research and Development Day to provide an extensive overview of the Company’s unique viral immunotherapy platforms and to review updated clinical data from its oncology-focused pipeline.

Read more at globenewswire.com

Related news for (CADL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.